BIOMEDICA SCLEROSTIN ELISA (Cat. No. BI-20492)
References / Publications

1. Calcification Propensity of Serum is Independent of Excretory Renal Function
Bernhard Bielesz, Thomas Reiter, Rodrig Marculescu, Andreas Gleiss, Marija Bojic, Heidi Kieweg, and Daniel Cejka
Sci Rep. 2017; 7: 17941.
PMID: 5738386

2. Periostin and sclerostin levels in juvenile Paget's disease
Stergios A. Polyzos, Polyzois Makras, Athanasios D. Anastasilakis, Gesthimani Mintziori, Marina Kita, Athanasios Papatheodorou Panagiotis Kokkoris and Evangelos Terpos
Clin Cases Miner Bone Metab. 2017 May-Aug; 14(2): 269–271.
PMCID: PMC5726226

3. A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective
Baoqi Yu, Stefan Kiechl, Dan Qi, Xiaocong Wang, Yanting Song, Siegfried Weger, Agnes Mayr, Alexandra Le Bras, Eirini Karamariti, Zhongyi Zhang, Ivan del Barco Barrantes, Christof Niehrs, Georg Schett, Yanhua Hu, Wen Wang, Johann Willeit, Aijuan Qu, and Qingbo Xu,
Circulation. 2017 Sep 12; 136(11): 1022–1036.
PMCID: PMC5598907

4. Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation
Lida Tartaglione, Marzia Pasquali, Silverio Rotondi, Maria Luisa Muci, Cristiana Leonangeli, Alessio Farcomeni, Valeria Fassino, and Sandro Mazzaferro
PLoS One. 2017; 12(5): e0178637.
PMCID: PMC5448809

5. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
Geert J. Behets, Liesbeth Viaene, Björn Meijers, Frank Blocki, Vincent M. Brandenburg, Anja Verhulst, Patrick C. D'Haese, and Pieter Evenepoel
PLOS ONE, 2017
PMID: 28493902

6. Sclerostin measurement in human disease: Validity and current limitations.
Aline G.Costa, SergeCremers, John P.Bilezikian
Bone, 2017, 24-28.
PMID: 27742501

7. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases
Mai Kawazoe, Kaichi Kaneko, Kotaro Shikano, Natsuko Kusunoki, Toshihiro Nanki, Shinichi Kawai
Clinical Rheumatology, 2017, 1-10
PMID: 28551822

8. Atypical skeletal manifestations of rickets in a familial hypocalciuric hypercalcemia patient
Bo Wu, Ou Wang, Yan Jiang, Mei Li, Xiaoping Xing, Weibo Xia,
Bone research, 2017
PMCID: PMC5486235

9. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis
Carlson N., Mortensen O.H., Axelsen M., Pedersen R.S., Heaf J.G.
Blood Purification, 2017, 122-128
PMID: 28690912

10. Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity
Athanasios D.Anastasilakis, Stergios A.Polyzos, Marina Tsoli, Athanasios Papatheodorou, Panagiotis Kokkoris, Gregory Kaltsas, Evangelos Terpos, Polyzois Makras
Metabolism, 2017, 198-201
PMID: 28521873

11. Serum sclerostin levels in renal cell carcinoma patients with bone metastases
C. Wibmer, K. Amrein, A. Fahrleitner-Pammer, M. M. Gilg, A. Berghold, G. C. Hutterer, W. Maurer-Ertl, A. Gerger, A. Leithner, M. Pichler and J. Szkandera
Sci Rep. 2016; 6: 33551.
PMCID: PMC5036091

12. Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass
Gabriella Császárné Gombos, Viktória Bajsz, Emese Pék, Béla Schmidt, Eszter Sió, Bálint Molics, and József Betlehem
BMC Musculoskelet Disord. 2016; 17: 254.
PMCID: PMC4899888

13. Idiopathic Acquired Osteosclerosis In A Middle-aged Woman With Systemic Lupus Erythematosus
Núria Guañabens, Steven Mumm, Laia Gifre, Silvia Ruiz Gaspà, Jennifer L. Demertzis, Marina Stolina, Deborah V. Novack and Michael P Whyte
J Bone Miner Res. 2016 Sep; 31(9): 1774–1782.
PMCID: PMC5010446

14. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients
Bang-Gee Hsu, Hung-Hsiang Liou, Chung-Jen Lee, Yen-Cheng Chen, Guan-Jin Ho, and Ming-Che Lee
Medicine (Baltimore). 2016 Apr; 95(15): e3300.
PMCID: PMC4839814

15. Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort.
Karine Briot, Adrien Etcheto, Corinne Miceli-Richard, Maxime Dougados, and Christian Roux
Rheumatology, 2016; 55: 335 – 342
PMID: 26361878

16. Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry
Abdulrahman Y. Almansouri,corresponding author Mohammed E. Abdulfatah, Omar H. Baaqil, Alaa A. Bakheet, Sarah A. Turki, Mamdouh M. Kotb, Alaa Althubaiti, Majed M. Almaghrabi, Abdulrahman M. Althubaiti, Badr M. Madani, and Ali S. M. Jawad
J Bone Metab. 2016 Feb; 23(1): 16–22.
PMCID: PMC4791433

17. Sclerostin as a novel marker of bone turnover in athletes
A Zagrodna, P Jóźków, M Mędraś, M Majda, and M Słowińska-Lisowska
Biol Sport. 2016 Mar; 33(1): 83–87
PMCID: PMC4763547

18. Sclerostin serum levels in patients with systemic autoimmune diseases
Concepción Fernández-Roldán, Fernanda Genre, Raquel López-Mejías, Begoña Ubilla, Verónica Mijares, Daniel Sánchez Cano, Concepción López Robles, José Luis Callejas-Rubio, Raquel Ríos Fernández, Manuela Expósito Ruiz, Miguel Á González-Gay, and Norberto Ortego Centeno
Bonekey Rep. 2016; 5: 775.
PMCID: PMC4747078

19. Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
Raphaèle Seror, Saida Boudaoud, Stephan Pavy, Gaetane Nocturne, Thierry Schaeverbeke, Alain Saraux, Philippe Chanson, Jacques-Eric Gottenberg, Valérie Devauchelle-Pensec, Gabriel J. Tobón, Xavier Mariette, and Corinne Miceli-Richarda
Sci Rep. 2016; 6: 18421.
PMCID: PMC4726234

20. How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits
Isabelle Piec, Christopher Washbourne, Jonathan Tang, Emily Fisher, Julie Greeves, Sarah Jackson, and William D. Fraser
Calcif Tissue Int. 2016; 98: 546–555.
PMCID: PMC4860200

21. Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients
Sebastian F. Mause, Annika Deck, Mark Hennies, Nadine Kaesler, Pieter Evenepoel, William A. Boisvert, Ulf Janssen and Vincent M. Brandenburg
Discoveries (Craiova). 2016; 4(1): e55.
PMCID: PMC4829955

22. Bone metabolism and renal stone risk during International Space Station missions
Scott M.Smith, Martina Heer, Linda C.Shackelford, Jean D.Sibonga, JordanSpatz, Robert A.Pietrzyk, Edgar K.Hudson, Sara R.Zwart.
Bone, 2015;712-720.
PMID: 26456109

23. Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort
Gaetane Nocturne, Stephan Pavy, Saida Boudaoud, Raphaèle Seror, Philippe Goupille, Philippe Chanson, Désirée van der Heijde, Floris van Gaalen, Francis Berenbaum, Xavier Mariette, Karine Briot, Antoine Feydy, Pascal Claudepierre, Philippe Dieudé, Joanne Nithitham, Kimberly E. Taylor, Lindsey A. Criswell, Maxime Dougados, Christian Roux, and Corinne Miceli-Richard
PLoS One. 2015; 10(8): e0134974.
PMCID: PMC4552086

24. Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone
Elżbieta Skowrońska-Jóźwiak, Krzysztof C. Lewandowski, Zbigniew Adamczewski, Kinga Krawczyk-Rusiecka, and Andrzej Lewiński
Int J Endocrinol. 2015; 2015: 948384.
PMCID: PMC4561097

25. Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race
Katharina Kerschan-Schindl, Markus M. Thalmann, Elisabeth Weiss, Maria Tsironi, Ursula Föger-Samwald, Johann Meinhart, Katerina Skenderi, and Peter Pietschmann
PLoS One. 2015; 10(7): e0132478.
PMCID: PMC4493015

26. Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
Wonjin Kim, Yoonjung Chung, Se Hwa Kim, Sehee Park, Jae Hyun Bae, Gyuri Kim, Su Jin Lee, Jo Eun Kim, Byeong-Woo Park, Sung-Kil Lim, and Yumie Rhee
Endocrinol Metab (Seoul). 2015 Mar; 30(1): 58–64.
PMCID: PMC4384667

27. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism
Giuseppe Daniele, Deidre Winnier, Andrea Mari, Jan Bruder, Marcel Fourcaudot, Zuo Pengou, Devjit Tripathy, Christopher Jenkinson, and Franco Folli
Diabetes Care, 2015; 38: 1509 - 1517.
PMID: 26456109

28. Association of Serum Sclerostin with Vascular Calcification in African Ancestry Men
Allison L Kuipers, Iva Miljkovic, J Jeffery Carr, James G Terry, Cara S Nestlerode, Yaorong Ge, Clareann H Bunker, Alan L Patrick, and Joseph M Zmuda
Circulation, 2015; 131: AP298.
PMID: 25618029

29. Serum Sclerostin levels are reduced by treatment with online postdilution hemodiafiltration
Camiel LM de Roij van Zuijdewijn, Muriel PC Grooteman, Marc G Vervloet, Menso J Nube, Peter J Blankestijn, Marinus A van den Dorpel, Denis Fouque, Solenne Pelletier, Michiel L Bots, and Piet M ter Wee
Nephrol. Dial. Transplant., 2015; 30: iii324.

30. High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis

Hartmut H. Malluche, Gustav Blomquist, Marie-Claude Monier-Faugere, Thomas L. Cantor, and Daniel L. Davenport
J. Am. Soc. Nephrol., 2015; 10.1681/ASN.2014070686.
PMID: 25838468

31. Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study
Tugba Tuylu, Ismail Sari, Dilek Solmaz, Didem Leyla Kozaci, Servet Akar, Necati Gunay, Fatos Onen, and Nurullah Akkoc
Clinics (Sao Paulo). 2014 Oct; 69(10): 688–693.
PMCID: PMC4221327

32. Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes
Theerawut Klangjareonchai, Hataikarn Nimitphong, Sunee Saetung, Nuttapimon Bhirommuang, Rattanapan Samittarucksa, Suwannee Chanprasertyothin, Rattana Sudatip, and Boonsong Ongphiphadhanakul
Int J Endocrinol. 2014; 2014: 261545.
PMCID: PMC4167818

33. The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
Se Hwa Kim, Soo Young Yoon, Sung-Kil Lim, and Yumie Rhee
Int J Endocrinol. 2014; 2014: 715908.
PMCID: PMC4099222

34. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5
C. A. Simpson, D. Foer, G. S. Lee, J. Bihuniak, B. Sun, R. Sullivan, J. Belsky, and K. L. Insogna
Osteoporos Int. 2014 Oct; 25(10): 2383–2388.
PMCID: PMC4659359

35. Serum Sclerostin in Hepatitis C Virus Infected Patients
Emilio González-Reimers, Javier López-Prieto, Ricardo Pelazas-González, M.Remedios Alemán-Valls, María José de la Vega-Prieto, Carlos Jorge-Ripper, M. Carmen Durán-Castellón, and F Santolaria-Fernández
J Bone Metab. 2014 Feb; 21(1): 69–75.
PMCID: PMC3970296

36. Serum Sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.
J Clin Endocrinol, 2014; 99(10): E1854–E1861
PMID: 25057883

37. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus
Antonino Catalano, Basilio Pintaudi, Nancy Morabito, Giacoma Di Vieste, Loretta Giunta, Maria Lucia Bruno, Domenico Cucinotta, Antonino Lasco, and Antonino Di Benedetto
Eur. J. Endocrinol., 2014; 171: 293 - 300.
PMID: 24891138

38. Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and Osteoporosis
Eva Klingberg, Merja Nurkkala, Hans Carlsten, and Helena Forsblad-d'Elia
J Rheumatol, 2014; 41: 1349 - 1356.
PMID: 24931960

39. Effect of supplemental vitamin D and calcium on serum sclerostin levels
Bess Dawson-Hughes, Susan S Harris, Lisa Ceglia, and Nancy J Palermo
Eur. J. Endocrinol., 2014; 170: 645 - 650.
PMID: 24488080

40. Renal elimination of sclerostin increases with declining kidney function
Daniel Cejka, Rodrig Marculescu, Nicolas Kozakowski, Max Plischke, Thomas Reiter, Alois Gessl, and Martin Haas
J. Clin. Endocrinol. Metab., 2014; 99: 248-255.
PMID: 24187403

41. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus
Agostino Gaudio, Filippo Privitera, Ivana Pulvirenti, Elena Canzonieri, Rosario Rapisarda, and Carmelo E Fiore
Diabetes and Vascular Disease Research, 2014; 11: 48-52.
PMID: 24227537

42. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
Liesbeth Viaene, Geert J. Behets, Kathleen Claes, Bjorn Meijers, Franck Blocki, V**in**cent Brandenburg, Pieter Evenepoel, and Patrick C. D'Haese
Nephrol. Dial. Transplant., 2013; 28: 3024 – 3030
PMID: 23605174

43. Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women
Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo Calleja, and Nerea Varo
J. Clin. Endocrinol. Metab., 2013; 98: E1740 - E1748.
PMID: 24001743

44. Elevated Sclerostin Levels Are Associated With Vertebral Fractures in Patients With Type 2 Diabetes Mellitus
Masahiro Yamamoto, Mika Yamauchi, and Toshitsugu Sugimoto
J. Clin. Endocrinol. Metab., 2013; 98: 4030 - 4037.
PMID: 23894157

45. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.
Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, and Saeda MY
Bone (2013), 56: 355-362.
PMID: 23845326

46. Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women
Claire Durosier, Antoon van Lierop, Serge Ferrari, Thierry Chevalley, Socrates

Papapoulos, and René Rizzoli
J. Clin. Endocrinol. Metab., 2013; 98: 3873 - 3883.
PMID: 23864703

47. Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
Sonia Morales-Santana, Beatriz García-Fontana, Antonia García-Martín, Pedro Rozas-Moreno, José Antonio García-Salcedo, Rebeca Reyes-García, and Manuel Muñoz-Torres
Diabetes Care, 2013; 36: 1667-1674.
PMID: 23288857

48. Relative Influence of Heritability, Environment and Genetics on Serum Sclerostin
Allison L. Kuipers, Yingze Zhang, Shibing Yu, Candace M. Kammerer, Cara S. Nestlerode, Yanxia Chu, Clareann H. Bunker, Alan L. Patrick, 4 Victor W. Wheeler, Iva Miljkovic, and Joseph M. Zmuda
Osteoporos Int. 2014 Mar; 25(3): 905–912.
PMCID: PMC3948173

49. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naïve Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-head Clinical Trial
Athanasios D. Anastasilakis, Stergios A. Polyzos, Athina Gkiomisi, Ilias Bisbinas, Spyridon Gerou, and Polyzois Makras
J. Clin. Endocrinol. Metab., 2013;98(8):3206-12.
PMID: 23788684

50. The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD
Solenne Pelletier, Laurence Dubourg, Marie-Christine Carlier, Aoumeur Hadj-Aissa, and Denis Fouque
Clin. J. Am. Soc. Nephrol., 2013; 8: 819-823.
PMID: 23430206

51. Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis
Antonino Catalano, Nancy Morabito, Giorgio Basile, Santa Brancatelli, Domenico Cucinotta, and Antonino Lasco
J. Clin. Endocrinol. Metab., 2013; 98: 1911-1915.
PMID: 23596142

52. Serum Sclerostin in Alcoholics: A Pilot Study
E. González-Reimers, C. Martín-González, M.J. de la Vega-Prieto, R. Pelazas-González, C. Fernández-Rodríguez, J. López-Prieto, J. Alvisa-Negrín, and F. Santolaria-Fernández
Alcohol Alcohol., May 2013; 48: 278-282.
PMID: 23296214

53. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The center of excellence for osteoporosis research

study.
MS Ardawi, AA Rouzi, SA Al-Sibiani, NS Al-Senani, MH Qari, and SA Mousa
J Bone Miner Res, Dec 2012; 27(12): 2592-2602.
PMID: 22836717

54. High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density.
E Voskaridou, D Christoulas, E Plata, C Bratengeier, A Anastasilakis, V Komninaka, D Kaliontzi, M Gkotzamanidou, SA Polyzos, M Dimopoulou, and E Terpos
Horm Metab Res, Nov 2012; 44(12): 909-913.
PMID: 22581647

55. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
D Gatti, O Viapiana, E Fracassi, L Idolazzi, C Dartizio, MR Povino, S Adami, and M Rossini
J Bone Miner Res, Nov 2012; 27(11): 2259-2263.
PMID: 22692843

56. Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels.
EB Skowro Ska-Jo Wiak, K Krawczyk-Rusiecka, KC Lewandowski, Z Adamczewski, and A Lewi Ski
Thyroid Res, Nov 2012; 5(1): 14.
PMID: 23146624

57. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase
Dagmar-Christiane Fischer, Anne Mischek, Sabrina Wolf, Anja Rahn, Birgit Salweski, Guenther Kundt, and Dieter Haffner
Ann Clin Biochem, Nov 2012; 49: 546-553.
PMID: 22984195

58. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
CG Saad, AC Ribeiro, JC Moraes, L Takayama, CR Goncalves, MB Rodrigues, RM Oliveira, CA Silva, E Bonfa, and RM Pereira
Arthritis Res Ther, Oct 2012; 14(5): R216.
PMID: 23062122

59. Strongly enhanced levels of sclerostin during human fracture healing.
K Sarahrudi, A Thomas, C Albrecht, and S Aharinejad
J Orthop Res, Oct 2012; 30(10): 1549-1555.
PMID: 22508529

60. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
Ali Taylan, Ismail Sari, Baris Akinci, Safak Bilge, Didem Kozaci, Servet Akar, Ayfer Colak, Hulya Yalcin, Necati Gunay, and Nurullah Akkoc
BMC Musculoskelet Disord. 2012; 13: 191.

PMCID: PMC3492209

61. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
E Terpos, D Christoulas, E Katodritou, C Bratengeier, M Gkotzamanidou, E Michalis, S Delimpasi, A Pouli, J Meletis, E Kastritis, K Zervas, and MA Dimopoulos
Int J Cancer, Sep 2012; 131(6): 1466-1471.
PMID: 22052418

62. Physical Activity in Relation to Serum Sclerostin, Insulin-Like Growth Factor-1, and Bone Turnover Markers in Healthy Premenopausal Women: A Cross-Sectional and a Longitudinal Study
Mohammed-Salleh M. Ardawi, Abdulrahim A. Rouzi, and Mohammed H. Qari
J. Clin. Endocrinol. Metab., Oct 2012; 97: 3691-3699.
PMID: 22865898

63. Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus
Agostino Gaudio, Filippo Privitera, Katia Battaglia, Venerando Torrisi, Maria Helga Sidoti, Ivana Pulvirenti, Elena Canzonieri, Giovanni Tringali, and Carmelo Erio Fiore
J. Clin. Endocrinol. Metab., Oct 2012; 97: 3744-3750.
PMID: 22855334

64. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
S Piemonte, E Romagnoli, C Bratengeier, W Woloszczuk, A Tancredi, J Pepe, C Cipriani, and S Minisola
J Endocrinol Invest, Oct 2012; 35(9): 866-868.
PMID: 22842667

65. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis
Diederik P C de Rooy, Nataliya G Yeremenko, Anthony Gerard Wilson, Rachel Knevel, Elisabet Lindqvist, Tore Saxne, Annemarie Krabben, Martha K Leijsma, Nina A Daha, S Tsonaka, A Zhernakova, J J Houwing-Duistermaat, Tom W J Huizinga, René E M Toes, Dominique L P Baeten, E Brouwer, and Annette H M van der Helm-van Mil
Ann Rheum Dis, Oct 2012; 10.1136/annrheumdis-2012-202184.
PMID: 23041840

66. Serum Sclerostin Increases in Healthy Adult Men during Bed Rest
J. M. Spatz, E. E. Fields, E. W. Yu, P. Divieti Pajevic, M. L. Bouxsein, J. D. Sibonga, S. R. Zwart, and S. M. Smith
J. Clin. Endocrinol. Metab., Sep 2012; 97: E1736-E1740.
PMID: 22767636

67. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib

monotherapy.
E Terpos, D Christoulas, E Katodritou, C Bratengeier, M Gkotzamanidou, E Michalis, S Delimpasi, A Pouli, J Meletis, E Kastritis, K Zervas, and MA Dimopoulos
Int J Cancer, Sep 2012; 131(6): 1466-1471
PMID: 22052418

68. Association of Circulating Sclerostin Levels with Fat Mass and Metabolic Disease—Related Markers in Japanese Postmenopausal Women
Tomohiko Urano, Masataka Shiraki, Yasuyoshi Ouchi, and Satoshi Inoue
J. Clin. Endocrinol. Metab., Aug 2012; 97: E1473-E1477.
PMID:22639287

69. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women.
Z Sheng, D Tong, Y Ou, H Zhang, Z Zhang, S Li, J Zhou, J Zhang, and E Liao
Clin Endocrinol (Oxf), Jun 2012; 76(6): 797-801.
PMID: 22151063

70. Nitroglycerin May Improve Bone Mass by Suppressing Sclerostin Levels
Aarthi Arasu, Celeste J Hamilton, Steven R Cummings, Richard Eastell, and Sophie A Jamal
Endocr. Rev., Jun 2012; 33: SAT-335.

71. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
MS Ardawi, AM Al-Sibiany, TM Bakhsh, AA Rouzi, and MH Qari
Osteoporos Int, Jun 2012; 23(6): 1789-1797.
PMID: 22041864

72. Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Luigi Gennari, Daniela Merlotti, Roberto Valenti, Elena Ceccarelli, Martina Ruvio, Maria G. Pietrini, Cosimo Capodarca, Maria Beatrice Franci, Maria Stella Campagna, Anna Calabro, Dorica Cataldo, Konstantinos Stolakis, Francesco Dotta,and Ranuccio Nuti
J Clin Endocrinol Metab, May 2012, 97(5):1737–1744.
PMID: 22399511

73. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
Gisela Ruiz Heiland,Heiner Appel,Denis Poddubnyy, Jochen Zwerina,Axel Hueber,Hildrun Haibel, Xenofon Baraliakos,Joachim Listing, Martin Rudwaleit,Georg Schett, Joachim Sieper
Ann Rheum Dis, 2012;71:572–574.
PMID: 22186710

74. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
YE Chung, SH Lee, SY Lee, SY Kim, HH Kim, FS Mirza, SK Lee, JA Lorenzo, GS Kim, and JM Koh.
Osteoporos Int, Apr 2012; 23(4): 1235-1243.
PMID: 21660558

75. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide.

SA Polyzos, AD Anastasilakis, C Bratengeier, W Woloszczuk, A Papatheodorou, and E Terpos.
Osteoporos Int, Mar 2012; 23(3): 1171-1176.
PMID: 21305266

76. Physical training increases osteoprotegerin in postmenopausal women.
I Bergstrom, P Parini, SA Gustafsson, G Andersson, and J Brinck
J Bone Miner Metab, Mar 2012; 30(2): 202-207.
PMID:21823052

77. Sclerostin levels during growth in children.
S Kirmani, S Amin, LK McCready, EJ Atkinson, LJ Melton 3rd, R Muller, and S Khosla
Osteoporos Int, Mar 2012; 23(3): 1123-1130.
PMID: 21617991

78. Association between sclerostin and bone density in chronic spinal cord injury.
LR Morse, S Sudhakar, V Danilack, C Tun, A Lazzari, DR Gagnon, E Garshick, and RA Battaglino.
Bone Miner Res, Feb 2012; 27(2): 352-359.
PMID: 22006831

79. Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy Adults.
Karin Amrein, Steven Amrein, Camilla Drexler, Hans Peter Dimai, Harald Dobnig, Klaus Pfeifer, Andreas Tomaschitz, Thomas R. Pieber, and Astrid Fahrleitner-Pammer
J. Clin. Endocrinol. Metab., Jan 2012; 97: 148-154.

80. Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus.
Antonia García-Martín, Pedro Rozas-Moreno, Rebeca Reyes-García, Sonia Morales-Santana, Beatriz García-Fontana, José A. García-Salcedo, and Manuel Muñoz-Torres
J. Clin. Endocrinol. Metab., Jan 2012; 97: 234-241.
PMID: 21994959

81. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 levels in patients with MGUS.
Alvin C. Ng, Sundeep Khosla, Natthinee Charatcharoenwitthaya, Shaji K. Kumar, Sara J., Achenbach, Margaret F. Holets, Louise K. McCready, L. Joseph Melton, Robert A. Kyle, S. Vincent Rajkumar, and Matthew T. Drake.
Blood, Dec 2011; 118: 6529-6534.
PMID: 22042700

82. Determinants of serum sclerostin in healthy pre- and postmenopausal women.
MS Ardawi, HA Al-Kadi, AA Rouzi, and MH Qari
J Bone Miner Res, Dec 2011; 26(12): 2812-2822.
PMID: 21812027

83. Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men.
Elaine W. Yu, Ruchit Kumbhani, Erica Siwila-Sackman, and Benjamin Z. Leder
J. Clin. Endocrinol. Metab., Nov 2011; 96: E1848-E1851.

PMID: 21865370

84. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
E Terpos, K Fragiadaki, M Konsta, C Bratengeier, A Papatheodorou, and PP Sfikakis
Clin Exp Rheumatol, Nov 2011; 29(6): 921-925.
PMID: 22032557

85. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women.
UI Modder, MM Roforth, K Hoey, LK McCready, JM Peterson, DG Monroe, MJ Oursler, and S Khosla.
Bone, Aug 2011; 49(2): 202-207.
PMID: 21550429

86. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high bone mass phenotype due to a mutation in Lrp5.
M Frost, T Andersen, F Gossiel, S Hansen, J Bollerslev, W Van Hul, R Eastell, M Kassem, and K Brixen.
J Bone Miner Res, Aug 2011; 26(8): 1721-1728.
PMID: 21351148

87. Comparisons of Serum Sclerostin Levels among Patients with Postmenopausal Osteoporosis, Primary Hyperparathyroidism and Osteomalacia.
H Kaji, Y Imanishi, T Sugimoto, and S Seino
Exp Clin Endocrinol Diabetes, Jul 2011; 119(7): 440-444.
PMID: 21667439

88. Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays.
Melissa McNulty, Ravinder J. Singh, Xujian Li, Eric J. Bergstralh, and Rajiv Kumar
J. Clin. Endocrinol. Metab., Jul 2011; 96: E1159-E1162.
PMID: 21543425

89. The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1.
Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Elena Fracassi, Maurizio Rossini, and Silvano Adami
J. Clin. Endocrinol. Metab., May 2011; 96: 1555-1559.
PMID: 21367927

90. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.
UI Modder, KA Hoey, S Amin, LK McCready, SJ Achenbach, BL Riggs, LJ Melton 3rd, and S Khosla.
J Bone Miner Res, Feb 2011; 26(2): 373-379.
PMID: 20721932

91. Regulation of circulating sclerostin levels by sex steroids in women and in men.
UI Modder, JA Clowes, K Hoey, JM Peterson, L McCready, MJ Oursler, BL Riggs, and S Khosla J
Bone Miner Res, Jan 2011; 26(1): 27-34.

PMID: 20499362

92. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin
Daniel Mendoza-Villanueva, Leo Zeef, and Paul Shore
Breast Cancer Res. 2011; 13(5): R106.
PMCID: PMC3262219

93. Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss.
Agostino Gaudio, Pietra Pennisi, Cornelia Bratengeier, Venerando Torrisi, Brigitte Lindner, Roberto, A. Mangiafico, Ivana Pulvirenti, Gerhard Hawa, Giovanni Tringali, and Carmelo E. Fiore
J. Clin. Endocrinol. Metab., May 2010; 95: 2248-2253.
PMID: 20305005

Congresses, Symposia:

Last Congress Abstract Update Oct 2012

ASBMR 2012 Minneapolis USA

ISN NEXUS Symposium 2012 "Bone and the Kidney" Copenhagen, Denmark (http://www.isnnexus.org/2012)

Summary of the Posters presented on Sclerostin- Biomedica ELISA References

Bone density and arterial stiffness are related to circulating sclerostin and Dickkopf-1 (DKK1) in pre-dialysis chronic kidney disease (CKD) patients
David J Goldsmith, Padmini Manghat, Anthony Wierzbicki, S Thambiah, R Roplekar, W Fraser, Geeta Hampson. *Renal, Theumatology, Biochemistry, King's Health Partners AHSC, London, United Kingdom.*
Poster # 15

Sclerostin and DKK-1 levels in pre-dialyisis CKD patients
Geert J Behts[1], Liesbeth Viaene[2], Bjorn Meijers[2], Patrick C D D'Haese[1], Pieter Evenepoel[2]. [1]Laboratory of Pathophysiology, University of Antwerp, Antwerp, Belgium, [2]Laboratory of Nephrology, Catholic University Leuven, Leuven, Belgium.
Poster # 89

Low PTH and high circulating sclerostin levels are independently associated with low bone specific alkaline phosphatase levels in hemodialysis patients
Liesbeth Viaene[1], Geert J Behets[2], Pieter Evenepoel[1], Patrick C D D'Haese[2].
[1]Laboratory of Nephrology, Catholic University Leuven, Leuven Belgium; [2]Labo Pathofysiologie, University of Antwerp, Antwerp, Belgium.
Poster # 90

Circulating sclerostin levels and vascular calcification in chronic kidney disease: A complex relationship
Kathleen J Claes[1], Liesbeth Viaene[1], Sam Heye[2], Björn Meijers[1], Patrick D'Haese[3], Pieter Evenepoel[1]. [1]Nephrology, University Hospitals Leuven, Leuven, Belgium; *[2]Radiology, University Hospitals Leuven, Leuven, Belgium; 3laboratory of Nephrology, University of Antwerp, Antwerp, Belgium.*
Poster # 91

Summary of Abstracts ECTS 2012 on Sclerostin Measurement Stockholm

PP183 – DIFFERENT PROFILES OF CIRCULATING SCLEROSTIN, IL-6 AND TNF-ALPHA AFTER HIP FRACTURE
T.J. Heino[1,2], S. Timlin[2], B. Sederquist[2], H. Aro[2]
[1]Department of Cell Biology and Anatomy; [2]Orthopaedic Research Unit, University of Turku, Turku, Finland

PP349 – WNT PATHWAY IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM
O. Viapiana, L. Idolazzi, C. Dartizio, G. Tripi, A. Fassio, I. Piazza, C. Caimmi, D. Gatti, S. Adami
Medicine, Rheumatology Section, University of Verona, Verona, Italy

PP363 – INCREASING LEVELS OF SERUM SCLEROSTIN, AN OSTEOCYTE-EXPRESSED NEGATIVE REGULATOR OF BONE FORMATION, ARE ASSOCIATED WITH ATHEROSCLEROTIC DISEASE IN TYPE 2 DIABETES
S. Morales[1,2], B. García-Fontana[1], A. García-Martín[1], P. Rozas-Moreno[3], J.A. García-Salcedo[1,4], R. Reyes-García[1], M. Muñoz-Torres[1]
[1]Bone Metabolic Unit (RETICEF), Endocrinology Division, Hospital Universitario San Cecilio; [2]Proteomic Research Service, Fundaciòn para la Investigaciòn Biosanitaria de Andalucía Oriental -Alejandro Otero- (FIBAO), Granada; [3]Endocrinology Division, Hospital General de Ciudad Real, Ciudad Real; [4]Molecular Biology, Instituto de Parasitología y Biomedicina ``López Neyra'', Granada, Spain

PP383 – SCLEROSTIN SERUM LEVELS ARE INCREASED IN PROSTATE CANCER PATIENTS
B. García-Fontana[1,2], S. Morales[1,3], M. Varsavsky[1], A. García-Martín[1], J.A. García-Salcedo[1,2,4], R. Reyes-García[1], M. Muñoz-Torres[1]

PP092 – CIRCULATING SERUM SCLEROSTIN LEVELS IN HEALTHY YOUNG WOMEN AFTER DIFFERENT KINDS OF PHYSICAL LOAD

J. Haschka[1], W. Woloszczuk[2], R. Kocijan[1], C. Muschitz[1], C. Bittighofer[1], A. Trubrich[1], S. Dinu[3], S. Kapiotis[3], H. Resch[1]
[1]The VINFORCE Study Group, St. Vincent Hospital; [2]Biomedica Group; [3]Central Laboratory St. Vincent Group, Vienna, Austria

OC21 – PHYSICAL ACTIVITY IN RELATION TO SERUM SCLEROSTIN, INSULIN-LIKE GROWTH FACTOR-1 AND BONE TURNOVER MARKERS IN HEALTHY PREMENOPAUSAL WOMEN: A CROSS-SECTIONAL AND A LONGITUDINAL STUDY

M.-S.M. Ardawi[1], A.A. Rouzi[2], M.H. Qari[3]
[1]Department of Clinical Biochemistry; [2]Department of Obstetrics and Gynecology; [3]Department of Haematology, Center of Excellence for Osteoporosis Research and Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia

OC49 – SERUM SCLEROSTIN LEVELS AND THE RISK OF OSTEOPOROTIC FRACTURES: THE CEOR STUDY

M.-S.M. Ardawi[1], A.A. Rouzi[2], S.A. Al-Sibiani[2], N.S. Al-Senani[2], M.H. Qari[3]
[1]Department of Clinical Biochemistry; [2]Department of Obstetrics and Gynecology; [3]Department of Haematology, Center of Excellence for Osteoporosis Research and Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia

Abstracts ASBMR 2011, San Diego:

Sclerostin/Renal Function/Diabetes:

Decreased Renal Function but Not Liver Function Overpowers the Circulating Sclerostin Level

ASBMR Sept 2011, # SU0406

Se Hwa Kim, Kwandong University College of Medicine, Myongji Hospital, South Korea; Hyeong Jin Kim, Kwandong University College of Medicine, Myongji Hospital, South Korea; Soo Young Yoon, Department of Internal Medicine, College of Medicine, Kwandong University, Myongji Hospital, South Korea; Sang Choel Lee, Department of Internal Medicine, College of Medicine, Kwandong University, Myongji Hospital, South Korea; Sung-Kil Lim, Yonsei University College of Medicine, South Korea; Yumie Rhee, Department of Internal Medicine, College of Medicine, Yonsei University, South Korea .

Serum Sclerostin Level and Its Association with Bone Turn-Over Markers in Type 2 Diabetes

ASBMR Sept 2011, # SA0324

Megumi Shibata, Fujita Health University, Division of Endocrinology, Japan; Atsushi Suzuki, Fujita. Health University Division of Endocrinology, Japan; Sahoko Sekiguchi-Ueda, Fujita Health University, Japan; Shogo Asano, Toyokawa City Hospital, Japan; Yasumasa Yoshino, Fujita Health University, Japan; Masaki Makino, Fujita Health University, Japan; Nobuki Hayakawa, Fujita Health University, Japan; Mitsuyasu Itoh, Fujita Health University, Japan

Circulating Levels of Sclerostin Are Increased in Patients With Type 2 Diabetes Mellitus

ASBMR Sept 2011, **#** SA0407

Antonia García-Martín, Bone Metabolic Unit. Endocrinology Division, Spain; Pedro Rozas-Moreno, Endocrinology Division. Hospital General de Ciudad Real. Ciudad Real, Spain., Spain; Sonia Morales-Santana, Proteomic Research Service. Hospital Universitario San Cecilio, Spain; Beatriz García-Fontana, Proteomic Research Service. Hospital

Universitario San Cecilio, Spain; JoséAntonio García-Salcedo, Bone Metabolic Unit (RETICEF). Endocrinology Division. Hospital Universitario San Cecilio, Spain; Rebeca Reyes, Bone Metabolic Unit, Spain; Manuel Munoz-Torres,University Hospital, Spain.

Circulating Sclerostin Levels and Bone Turnover in Type 1 and 2 Diabetes
ASBMR Sept 2011**, #** FR0394
Ranuccio Nuti, University of Siena, Italy; Roberto Valenti, S. Maria Alle Scotte Hospital, Italy; Daniela Merlotti, University of Siena, Italy; Elena Ceccarelli, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Martina Ruvio, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Maria Giulia Pietrini, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Cosimo Capodarca, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Maria Beatrice Franci, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Anna Calabrò, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Konstantinos Stolakis, Dept. Internal Medicine
Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Francesco Dotta, Dept. Internal Medicine Endocrine Metabolic Sciences and Biochemistry University of Siena, Italy; Luigi Gennari, University of Siena, Italy.

Sclerostin/Regulation/Bone Mineral Desity/Bone Mass

Circulating Sclerostin Demonstrates a Circadian Rhythm in Young Healthy Men
ASBMR Sept 2011, # SU0389
Shankar Narayan H Santosh, The Royal Liverpool University Hospital, GBR; Frank Joseph,
Countess of Chester Hospital NHS Trust, United Kingdom; Amanda Hamilton, Royal Liverpool University Hospital, United Kingdom; Brian Durham, University of Liverpool, United Kingdom; Anna Robinson, University of Liverpool, United Kingdom; Jonathan Tang, Royal Liverpool University Hospital, United Kingdom; Jiten P Vora, Royal Liverpool University Hospital, United Kingdom; William D Fraser, Department of Clinical Chemistry, University of Liverpool, United Kingdom.

Sclerostin Is Associated with Age, BMI and Bone Mineral Content, but Not Gender or Physical Activity in Healthy Adults
ASBMR Sept 2011, # SU0346
Karin Amrein, Medical University of Graz, Austria; Astrid Fahrleitner-Pammer, Medical University Graz, Austria; Steven Amrein, Medical University of Graz, Austria, Department of Anaesthesiology and Intensive Care Medicine, Austria; Camilla Drexler, Medical University of Graz, Austria, University Clinic of Blood Group Serology and Transfusion Medicine, Austria; Hans Dimai, Medical University Graz, Austria; Thomas R Pieber, Medical University of Graz, Austria, Division of Endocrinology and Metabolism, Department of Internal Medicine, Austria; Andreas Tomaschitz, Medical University of Graz, Austria, Division of Endocrinology and Metabolism, Department of Internal Medicine, Austria; Harald Dobnig, Diagnostikinstitut Dr.B.Fueger, Institute for Endocrine and Bone Diseases, AUT.

Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men
ASBMR Sept 2011, **#** MO0120
Elaine Yu, Massachusetts General Hospital, USA; Ruchit Kumbhani, MGH Endocrine Unit, USA; Erica Siwila-Sackman, MGH Endocrine Unit, USA; Benjamin Leder, Massachusetts General Hospital Harvard Medical School, USA.

Circulating Sclerostin Correlates to Bone Mineral Mass, Micro-Structure and Turnover in Healthy Elderly Men and Women
ASBMR Sept 2011**, #** SA0393
Claire Durosier, Hopitaux Universitaires de Geneve, Switzerland; Antoon Van Lierop, Leiden
University Medical Center, The Netherlands; Serge Ferrari, Geneva University Hospital and Faculty of Medicine, Switzerland; Thierry Chevalley, University Hospitals of Geneva Division of Bone Diseases, Switzerland; Socrates Papapoulos, Leiden University Medical Center, The Netherlands; Rene Rizzoli, University Hospital, Switzerland.

Serum Sclerostin Levels Correlate Positively with Bone Mineral Density at Multiple SkeletalSites in Postmenopausal Women
ASBMR Sept 2011, # SU0410
Faryal Mirza, University of Connecticut Health Center, USA; Anne Kenny, University of Connecticut, USA; Pamela Taxel, University of Connecticut Health Center, USA; Joseph Lorenzo, University of Connecticut Health Center, USA.

Positive Association Between Circulating Sclerostin and Bone Mass in Chronic Spinal Cord Injury: Evidence Against Sclerostin as a Target To Treat Chronic Disuse Osteoporosis
ASBMR Sept 2011, # MO0063
Leslie Morse, Department of Physical Medicine and Rehabilitation, Harvard Medical School,
Spaulding Rehabilitation Hospital, USA; Supreetha Sudhakar, Spaulding Rehabilitation Hospital, USA; Valery Danilack, Programs in Research at VA Boston, USA; Carlos Tun, Rehabilitation Medicine Service, USA; Antonio Lazzari, Primary Care Section, VA Boston Healthcare System and Boston University School of Medicine, USA; David Gagnon, VA Cooperative Studies Program, VA Boston Healthcare System, Department of Biostatistics, Boston University School of Public Health,USA; Eric Garshick, Pulmonary and Critical Care Medicine Section, Medical Service, VA Boston Healthcare System, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA; Ricardo Battaglino, The Forsyth Institute, USA.

Elevated Sclerostin in Individuals with High Bone Mass
ASBMR Sept 2011, # SU0158
Celia Gregson, University of Bristol, United Kingdom; Kenneth Poole, University of Cambridge, United Kingdom; Susan Steel, Hull & E Yorks Hospital Trust, United Kingdom; John Ayuk, University Hospitals Birmingham NHS Foundation Trust, United Kingdom; Emma Duncan, Royal Brisbane and Women's Hospital, Australia; Eugene McCloskey, University of Sheffield, United Kingdom; William Fraser, Norwich Medical School, University of East Anglia, United Kingdom; JH Tobias, Avon Orthopaedic Centre, United Kingdom.

Sclerostin/Therapies/Diseases

Long-Term Treatment with Raloxifene, but Not Bisphosphonates, Reduces Circulating Sclerostin Levels in Postmenopausal Women
ASBMR Sept 2011, # SA0395
Hong-Hee Kim, Seoul National University, South Korea; Yun Ey Chung, Department of Internal Medicine, Seoul Veterans Hospital, South Korea; Sun-Kyeong Lee, Division of Endocrinology,University of Connecticut Health Center, USA; Sun-Young Lee, Asan Institute for Life Sciences, South Korea; Seung Hun Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea; Ghi Su Kim, Asan Medical Center, University of Ulsan College of Medicine, South Korea; Shin-Yoon Kim, Kyungpook National University Hospital, South Korea; Faryal S Mirza, Division of Endocrinology, University of

Connecticut Health Center, USA; Jung-Min Koh, Asan Medical Center, South Korea; Joseph A Lorenzo, Division of Endocrinology, University of Connecticut Health Center, USA.

Aromatase Inhibitor Significantly Increased Circulating Sclerostin Level in Patients with Endocrine-Responsive Breast Cancer
ASBMR Sept 2011, # SA0406
Yumie Rhee, Department of Internal Medicine, College of Medicine, Yonsei University, South Korea; Yoon Jung Chung, Brain Korea 21 Project for Medical Science, Yonsei University, South Korea; Se Hwa Kim, Kwandong University College of Medicine, Myongji Hospital, South Korea; Sung-Kil Lim, Department of Internal Medicine, College of Medicine, Yonsei University, South Korea; Byeong Woo Park, Department of Surgery, College of Medicine, Yonsei University, South Korea.

The Effect of Glucocorticoid Therapy on Regulators of Bone Formation in Postmenopausal Women Treated with Teriparatide or Alendronate.
ASBMR Sept 2011, # 1252
Fatma Gossiel, The University of Sheffield, United Kingdom; Nancy Lane, University of California, Davis Medical Center, USA; Richard Eastell, University of Sheffield, United Kingdom.

Determination of Serum Sclerostin Levels in Women with Anorexia Nervosa
ASBMR Sept 2011, # MO0397
Christina Bittighofer, The VINFORCE Study Group - St. Vincent Hospital – Medical Department II, Academic Teaching Hospital of the Medical University of Vienna, Austria; Julia Wild, Medical University of Vienna, Department of Obstetrics and Gynecology, Austria;
Angela Trubrich, The VINFORCE Study Group - St. Vincent Hospital – Medical Department II, Academic Teaching Hospital of the Medical University of Vienna, Austria; Judith Haschka, St. Vincent's Hospital, Austria; Roland Kocijan, St.Vincent Hospital Vienna, Austria; Wolfgang Woloszczuk, Biomarker Design ForschungsGmbH, Vienna, Austria, Austria; Stylianos Kapiotis, Central Laboratory St. Vincent Group, Austria; Sebastian Dinu, Central Laboratory St. Vincent Group, Austria; Christian Muschitz, St. Vincent's Hospital, Austria; Heinrich Resch, Medical University Vienna, Austria.

Determination and Comparison of Serum and Plasma Sclerostin Concentrations by Commercially Available Enzyme-Linked Immunoassays
ASBMR Sept 2011 #MO0188
Melissa McNulty, Mayo Clinic, USA; Ravinder Singh, Mayo Clinic, USA; Eric Bergstralh, Mayo Clinic, USA; Xujian Li, Mayo Clinic, USA; Rajiv Kumar, Mayo Clinic College of Medicine, USA.

Abstracts ASBMR 2010/Toronto:

Effects of Estrogen on Bone Marrow Cytokines/Bone-regulatory Factors and Osteoprogenitor Cells in Vivo in Elderly Women.
ASBMR Oct 2010 Abstract # 1035
Ulrike I. Moedder, Louise McCready, Kelley Hoey, Matthew Roforth, James Peterson, Sundeep Khosla.

Gender Differences in Circulating Sclerostin Levels are Established During Puberty and Correlate with Cortical Porosity.
ASBMR Oct 2010 Abstract # 1178

Salman Kirmani, Ulrike I. Moedder, Kelley Hoey, James Peterson, Louise McCready, Atkinson Elizabeth, Shreyasee Amin, L Joseph Melton, Byron Lawrence Riggs, Ralph Müller, Sundeep Khosla.

Estrogen, but not Testosterone, Suppresses Circulating Sclerostin Levels in Humans.
ASBMR Oct 2010 Abstract # 1134
Ulrike I. Moedder, Jackie A. Clowes, Kelley Hoey, James Peterson, Louise McCready, Merry Jo Oursler, Byron Lawrence Riggs, Sundeep Khosla.

Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men.
ASBMR Oct 2010 Abstract # 1091
Ulrike I. Moedder, Kelley Hoey, Shreyasee Amin, Louise McCready, L. Joseph Melton, Byron
Lawrence Riggs, Elizabeth Atkinson, Sundeep Khosla.

Regulators of Bone Formation in Postmenopausal Oseoporosis: Effect of Bisphosphonate Treatment.
ASBMR Oct 2010 Abstract #1100
Richard Eastell, Rosemary A. Hannon, Fatma Gossiel.
Estradiol Replacement Therapy Lowers Serum Sclerostin Levels in Postmenopausal Women.
ASBMR Oct 2010 Abstract # SA0368
Faryal S. Mirza, Pamela Taxel, Yun Ey Chung, Sandra Jastrzebski, Univ of Connecticut Health Center, Lawrence G. Raisz, Joseph Lorenzo.

Abstracts ASH 2009/2010:

Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib.
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2963.
Evangelos Terpos, Dimitrios Christoulas, Maria Gkotzamanidou, Cornelia Bratengeier, Maria Gavriatopoulou, Magdalini Migkou, Athanasios Papatheodorou, Efstathios Kastritis, Wolfgang Woloszczuk, and Meletios A. Dimopoulos.

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia.
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1010.
Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Cornelia Bratengeier, Eleni Plata, Despoina Kaliontzi, Wolfgang Woloszczuk, and Evangelos Terpos.

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 425.
Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, Cornelia Bratengeier, Brigitte Lindner, Silvia Harmelin, Gerhard Hawa, Georgios Boutsikas, Magdalini Migkou, Maria Gavriatopoulou, Eurydiki Michalis, Anastasia Pouli, Efstathios Kastritis, Konstantinos Zervas, and Meletios A. Dimopoulos.